glp-1 australia RA and GIP + GLP-1 RA injections current evidence and uses in – Dr. Victor Liew GLP-1 drug Mounjaro's billion dollar

doi: 10.3389/fendo.2022.1004044 Received 26 July 2022 Accepted 27 September 2022 Published 13 October 2022 Volume 13 - 2022 Edited by ke Sjholm, Gvle Hospital, Sweden Reviewed by Finbarr P

Hemmer, A., Maiter, D., Buysschaert, M., & Preumont, V

Exenatide was the first GLP-1, prescribed under the brand name Byetta, in 2005, to treat Type-2 diabetes

This weight reduction is particularly beneficial for non-diabetic individuals as well, helping to lower the risk of developing obesity-related conditions

Antiobesity drug therapy can be used in conjunction with a low-calorie diet and increased physical activity to manage weight in adults with a BMI of 30 kg/m 2 or 2730 kg/m 2 with weight-related comorbidity, such as dysglycemia, hypertension, dyslipidemia, or obstructive sleep apnea